These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 23169228

  • 41. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease.
    Wenning GK, Bösch S, Luginger E, Wagner M, Poewe W.
    Adv Neurol; 1999; 80():545-8. PubMed ID: 10410769
    [No Abstract] [Full Text] [Related]

  • 42. Practical considerations in the use of apomorphine injectable.
    Bowron A.
    Neurology; 2004 Mar 23; 62(6 Suppl 4):S32-6. PubMed ID: 15037670
    [Abstract] [Full Text] [Related]

  • 43. Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson's disease.
    Grandas F.
    Expert Rev Neurother; 2013 Dec 23; 13(12):1343-53. PubMed ID: 24160681
    [Abstract] [Full Text] [Related]

  • 44. Acute lethargy after abrupt apomorphine withdrawal in Parkinson's disease.
    Cavallieri F, Fraix V, Meoni S, Krack P, Moro E, Castrioto A.
    J Neurol Sci; 2019 Sep 15; 404():44-46. PubMed ID: 31325667
    [No Abstract] [Full Text] [Related]

  • 45. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations.
    Nyholm D, Constantinescu R, Holmberg B, Dizdar N, Askmark H.
    Acta Neurol Scand; 2009 May 15; 119(5):345-8. PubMed ID: 18822087
    [Abstract] [Full Text] [Related]

  • 46. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results.
    Stocchi F, Vacca L, De Pandis MF, Barbato L, Valente M, Ruggieri S.
    Neurol Sci; 2001 Feb 15; 22(1):93-4. PubMed ID: 11487217
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ, Turner K, Lees AJ.
    Mov Disord; 2002 Nov 15; 17(6):1235-41. PubMed ID: 12465062
    [Abstract] [Full Text] [Related]

  • 55. Quality of life in Parkinson's disease improved by apomorphine pump: the OPTIPUMP cohort study.
    Drapier S, Eusebio A, Degos B, Vérin M, Durif F, Azulay JP, Viallet F, Rouaud T, Moreau C, Defebvre L, Fraix V, Tranchant C, Andre K, Courbon CB, Roze E, Devos D.
    J Neurol; 2016 Jun 15; 263(6):1111-9. PubMed ID: 27060084
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Apomorphine-subcutaneous--Bertek/Britannia.
    Drugs R D; 2004 Jun 15; 5(4):211-2. PubMed ID: 15230626
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Infusional Therapies, Continuous Dopaminergic Stimulation, and Nonmotor Symptoms.
    Mundt-Petersen U, Odin P.
    Int Rev Neurobiol; 2017 Jun 15; 134():1019-1044. PubMed ID: 28805563
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.